PURPOSE: To determine the pharmacokinetics of SAR 1118, a small-molecule antagonist of leukocyte function-associated antigen (LFA)-1, after administration of ophthalmic drops in normal rats, and to determine its pharmacologic activity by assessing the inhibition of retinal leukostasis and vascular leakiness in a streptozotocin (STZ)-induced diabetic retinopathy model. METHODS: The ocular pharmacokinetics of SAR 1118 were studied in rats after a single topical dose of (14)C-SAR 1118 (1 mg/eye; 40 μCi; 15.5 μL). SAR 1118 concentration time profiles in plasma and ocular tissues were quantified by liquid scintillation counting (LSC). The pharmacologic activity of SAR 1118 eye drops administered thrice daily for 2 months at 1% (0.3 mg/eye/d) and 5% (1.5 mg/eye/d) was assessed in an STZ-induced diabetic rat model by determining retinal leukostasis and blood-retinal barrier breakdown. Diabetic rats treated with periocularly administered celecoxib microparticles served as the positive control, and vehicle-treated rats served as the negative control. RESULTS: A single dose of 6.5% (14)C-radiolabeled SAR 1118 ophthalmic drops delivered retinal drug levels greater than 1 μM in less than 30 minutes and sustained levels greater than 100 nM for 8 hours. SAR 1118 eye drops significantly reduced leukostasis and blood-retinal barrier breakdown in a dose-dependent manner. CONCLUSIONS: SAR 1118 ophthalmic drops administered thrice daily deliver therapeutic levels of SAR 1118 in the retina and can alleviate the retinal complications associated with diabetes.
PURPOSE: To determine the pharmacokinetics of SAR 1118, a small-molecule antagonist of leukocyte function-associated antigen (LFA)-1, after administration of ophthalmic drops in normal rats, and to determine its pharmacologic activity by assessing the inhibition of retinal leukostasis and vascular leakiness in a streptozotocin (STZ)-induced diabetic retinopathy model. METHODS: The ocular pharmacokinetics of SAR 1118 were studied in rats after a single topical dose of (14)C-SAR 1118 (1 mg/eye; 40 μCi; 15.5 μL). SAR 1118 concentration time profiles in plasma and ocular tissues were quantified by liquid scintillation counting (LSC). The pharmacologic activity of SAR 1118 eye drops administered thrice daily for 2 months at 1% (0.3 mg/eye/d) and 5% (1.5 mg/eye/d) was assessed in an STZ-induced diabeticrat model by determining retinal leukostasis and blood-retinal barrier breakdown. Diabeticrats treated with periocularly administered celecoxib microparticles served as the positive control, and vehicle-treated rats served as the negative control. RESULTS: A single dose of 6.5% (14)C-radiolabeled SAR 1118 ophthalmic drops delivered retinal drug levels greater than 1 μM in less than 30 minutes and sustained levels greater than 100 nM for 8 hours. SAR 1118 eye drops significantly reduced leukostasis and blood-retinal barrier breakdown in a dose-dependent manner. CONCLUSIONS:SAR 1118 ophthalmic drops administered thrice daily deliver therapeutic levels of SAR 1118 in the retina and can alleviate the retinal complications associated with diabetes.
Authors: Timothy S Kern; Casey M Miller; Yunpeng Du; Ling Zheng; Susanne Mohr; Sherry L Ball; M Kim; Jeffrey A Jamison; David P Bingaman Journal: Diabetes Date: 2007-02 Impact factor: 9.461
Authors: Aniruddha C Amrite; Surya P Ayalasomayajula; Narayan P S Cheruvu; Uday B Kompella Journal: Invest Ophthalmol Vis Sci Date: 2006-03 Impact factor: 4.799
Authors: K Miyamoto; S Khosrof; S E Bursell; R Rohan; T Murata; A C Clermont; L P Aiello; Y Ogura; A P Adamis Journal: Proc Natl Acad Sci U S A Date: 1999-09-14 Impact factor: 11.205
Authors: D M Paskowitz; Q D Nguyen; P Gehlbach; J T Handa; S Solomon; W Stark; O Shaikh; C Semba; T R Gadek; D V Do Journal: Eye (Lond) Date: 2012-04-27 Impact factor: 3.775
Authors: Roxane J Hillier; Elvis Ojaimi; David T Wong; Michael Y K Mak; Alan R Berger; Radha P Kohly; Peter J Kertes; Farzin Forooghian; Shelley R Boyd; Kenneth Eng; Filiberto Altomare; Louis R Giavedoni; Rosane Nisenbaum; Rajeev H Muni Journal: JAMA Ophthalmol Date: 2018-04-01 Impact factor: 7.389
Authors: Min Zhong; Thomas R Gadek; Minna Bui; Wang Shen; John Burnier; Kenneth J Barr; Emily J Hanan; Johan D Oslob; Chul H Yu; Jiang Zhu; Michelle R Arkin; Marc J Evanchik; W Mike Flanagan; Ute Hoch; Jennifer Hyde; Saileta Prabhu; Jeffrey A Silverman; Jasmin Wright Journal: ACS Med Chem Lett Date: 2012-01-31 Impact factor: 4.345